Anderson–Fabry disease: Clinical manifestations of disease in female heterozygotes
Tóm tắt
Anderson–Fabry disease is a rare, X-chromosomal lipid storage disorder caused by a deficiency of lysosomal α-galactosidase A. Clinical manifestations of Anderson–Fabry disease include excruciating pain in the extremities (acroparaesthesia), skin vessel ectasia (angiokeratoma), corneal and lenticular opacity, cardiovascular disease, stroke and renal failure, only renal failure being a frequent cause of death. Heterozygote female carriers have often been reported as being asymptomatic or having an attenuated form of the disease. To evaluate the spectrum of clinical signs in heterozygotes, a comprehensive clinical examination was performed on 20 carriers of Anderson–Fabry disease. This revealed that, in addition to the skin manifestation, various other clinical manifestations of the disease are present, including acroparaesthesia, kidney dysfunction, cerebrovascular disease, and gastrointestinal and heart problems. It therefore appears that Anderson–Fabry disease affects both hemizygotes and heterozyotes and therefore should be considered to be an X-linked dominant disease.
Tài liệu tham khảo
Beck G (1980) Beitrag zur Fabryschen Krankheit. Schweiz Med Wochenschr 110(33): 1190-1201.
Bird TD, Lagunoff D (1978) Neurological manifestations of Anderson Fabry disease in female carriers. Ann Neurol 4(6): 537-540.
Bishop DF, Kornreich R, Desnick RJ (1988) Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3′ untranslated region. Proc Natl Acad Sci USA 85(11): 3903-3907.
Bunge S, Fuchs S, Gal A (1996) Simple and nonisotopic methods to detect unknown gene mutations in nucleic acids. In Adolph KW, ed. Methods in Molecular Genetics, vol. 8. Orlando: Academic Press, 26-39.
Burda CD, Winder PR (1967) Angiokeratoma corporis diffusum universale (Fabry's disease) in female subjects. Am J Med 42(2): 293-301.
Carter N, Milroy CM, Shepherd RT (1995) Sudden death in elderly women with Fabry's disease. Am J Forensic Med Pathol 16(1): 21-26.
Castro LH, Monteiro ML, Barbosa ER, et al (1994) Fabry's disease in a female carrier with bilateral thalamic infarcts: a case report and a family study. Rev Paul Med 112(4): 649-653.
El-Shahawy MA, Mesa C, Koss M, et al (1996) A 19-year-old female with fever, acroparesthesia, and progressive deterioration of renal function. Am J Nephrol 16(5): 417-424.
Eng CM, Banikazemi M, Gordon RE, et al (2001) A phase 1/2 clinical trial of enzyme replacement in Anderson Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68: 711-722.
Favier R, Lavergne JM, Costa JM, et al (2000) Unbalanced X-chromosome inactivation with a novel FVIII gene mutation resulting in severe hemophilia A in a female. Blood 96: 4373-4375.
Fukushima M, Tsuchiyama Y, Nakato T, et al (1995) A female heterozygous patient with Fabry's disease with renal accumulation of trihexosylceramide detected with a monoclonal antibody. Am J. Kidney Dis 26(6): 952-955.
Grewal RP (1993) Psychiatric disorders in patients with Fabry's disease. Int J Psychiatry Med 23(3): 307-312.
Grewal RP, McLatchey SK (1992) Cerebrovascular manifestations in a female carrier of Fabry's disease. Acta Neurol Belg 92(1): 36-40.
Hasholt L, Sorensen SA, Wandall A, et al (1990) A Fabry's disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations. J Med Genet 27(5): 303-306.
Knol IE, Ausems MG, Lindhout D, et al (1999) Different phenotypic expression in relatives with Anderson Fabry disease caused by a W226X mutation. Am J Med Genet 82(5): 436-439.
Koitabashi N, Utsugi T, Seki R, et al (1999) Biopsy-proven cardiomyopathy in heterozygous Fabry's disease. Jpn Circ J 63(7): 572-575.
Larregue M, Trincal D, Bressieux, JM, et al (1991) Early acroparesthesia in females: a sign disclosing heterozygote Anderson Fabry disease. Ann Dermatol Venereol 118(3): 191-197.
Lewin MB, Belmont J, McNamara DG, et al (1999) Further associations of congenital heart disease and genetic syndromes: report of a case of tetralogy of Fallot and Fabry's disease (letter). Pediatr Cardiol 20(3): 236-237.
Majima K, Ishizaki T, Inoue T, et al (1992) A case of Fabry's disease associated with lupus nephritis. Nippon Jinzo Gakkai Shi 34(11): 1189-1194.
Morgan SH, Rudge P, Smith SJ, et al (1990) The neurological complications of Anderson Fabry disease (alpha-galactosidase A deficiency) investigation of symptomatic and presymptomatic patients. Q J Med 75(277): 491-507.
Murata R, Takatsu H, Noda T, et al (1999) Fifteen-year follow-up of a heterozygous Fabry's disease patient associated with pre-excitation syndrome. Intern Med 38(6): 476-481.
Nakao S, Takenaka T, Maeda M, et al (1995) An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333(5): 288-293.
Nakayama Y, Tsumura K, Yamashita N, et al (1999) Dynamic left ventricular arterial pressure gradient and sick sinus syndrome with heterozygous Fabry's disease improved following implantation of a dural chamber pacemaker. Pacing Clin Electrophysiol 22(7): 1114-1115.
Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, et al (1996) Uneven X inactivation in a female monozygotic twin pair with Anderson Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet 33(8): 682-688.
Rodriguez FH, Jr., Hoffmann EO, Ordinario AT Jr, et al (1985) Fabry's disease in a heterozygous woman. Arch Pathol Lab Med 109(1): 89-91.
Rosenmann E, Kobrin I, Cohen T (1983) Kidney involvement in systemic lupus erythematosus and Fabry's disease. Nephron 34(3): 180-184.
Schiffmann R, Murray GJ, Treco D, et al (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Anderson Fabry disease. Proc Natl Acad Sci USA 97(1): 365-370.
Sharp A, Robinson D, Jacobs P (2000) Age-and tissue-specific variation of X chromosome inactivation ratios in normal women. Hum Genet 107: 343-349.
Sher NA, Letson RD, Desnick RJ (1979) The ocular manifestations in Fabry's disease. Arch Ophthalmol 97(4): 671-676.
Singh HK, Nickeleit V, Kriegsmann J, et al (2001) Coexistence of Fabry's disease and necrotizing and crescentic glomerulonephritis. Clin Nephrol 55: 73-79.
Van Loo A, Vanholder R, Madsen M, et al (1996) Novel frameshift mutation in a heterozygous woman with Anderson Fabry disease and end-stage renal failure. Am J Nephrol 16(4): 352-357.
Vetrie D, Bentley D, Bobrow M, et al (1993) Physical mapping shows close linkage between the alpha-galactosidase A gene (GLA) and the DXS 178 locus. Hum Genet 92(1): 95-99.
Wadskov S, Andersen V, Kobayasi T, et al (1975) On the diagnosis of Fabry's disease. Acta Derm Venereol 55(5): 363-366.
Wagrowska-Danilewicz M, Danilewicz M, Gozdzik Z (1999) The ultrastructural changes in renal biopsy compatible with Fabry's disease. Case report. Pol J Pathol 50(1): 61-63.
Wherrett JR, Hakomori SI (1973) Characterization of a blood group B glycolipid, accumulating in the pancreas of a patient with Fabry's disease. J Biol Chem 248: 3046-3051.
Yoshida A, Morozumi K, Takeda A, et al 1994) Fabry-like laminated myelin body associated with IgA nephropathy. Nippon Jinzo Gakkai Shi 36(11): 1303-1307.
Yoshioka M, Yorifuji T, Mituyoshi I (1998) Skewed X inactivation in manifesting carriers of Duchenne muscular dystrophy. Clin Genet 53: 102-107.
Yuen NW, Lam CW, Chow TC, et al (1997) A characteristic dissection microscopy appearance of a renal biopsy of a Fabry heterozygote. Nephron 77(3): 354-356.